Highlights

  • Revenue from ordinary activities grew 28.4% to $124.8 million in 1H FY2026, with underlying profit before tax up 29.7% to $90.7 million and EBIT margins expanding to 73%.
  • Seven new contracts were signed during the period with a combined minimum value exceeding $280 million, including the company's first cardiology contracts and its largest-ever deal at $170 million with University of Colorado.
  • The company remains debt-free with cash and other financial assets of $221.8 million, and declared a fully franked interim dividend of 32 cents per share.

 

Company Overview

Pro Medicus Limited (ASX: PME) is a leading healthcare informatics company founded in 1983 and headquartered in Melbourne. The company provides medical imaging software and services to hospitals, imaging centres, and healthcare groups worldwide through its Visage 7 suite of products. The Visage 7 platform encompasses a radiology information system (RIS), picture archiving and communications system (PACS), workflow management, and archive capabilities, delivered in a cloud-native architecture that the company describes as ultra-fast, clinically rich, and highly scalable. Following its acquisition of Visage Imaging in January 2009, Pro Medicus transformed itself from an Australian software vendor into a global provider of enterprise medical imaging solutions, primarily targeting large academic medical centres and integrated delivery networks (IDNs) in the United States — its largest and highest-growth market.

Financial Performance: Another Record Half

Pro Medicus delivered what CEO Dr Sam Hupert described as another record result for the half-year ended 31 December 2025. Revenue from ordinary activities reached $124.8 million, an increase of 28.4% over the prior corresponding period. Underlying profit before tax was $90.7 million, up 29.7%, while underlying net profit after tax was $67.3 million, also up 29.7%. These underlying figures strip out a material non-recurring item: the company's $10 million hybrid debt and equity investment in 4DMedical Limited, made in July 2025, generated unrealised pre-tax gains of $149.1 million by the end of December 2025. As a result, statutory net profit after tax was $171.2 million, up 230.9%, though this figure is not representative of the company's recurring operational earnings.

EBIT margins on an underlying basis increased to 73%, up from 72% in the prior corresponding half year. For a software company of PME's scale, achieving incremental margin expansion at such elevated absolute levels is a notable feat and reflects the leverage characteristics of the company's transaction-based revenue model, under which revenue scales with scan volumes while the cost base grows at a substantially slower rate. Cash and other financial assets at 31 December 2025 were $221.8 million, an increase of 5.3% despite the company paying increased dividends, completing two share buybacks, and funding the $10 million 4DMedical investment during the period. The company remains entirely debt-free.

Contract Activity: A Record Pipeline of New Business

The volume and value of new contracts signed during 1H FY2026 was exceptional. Seven new contracts were announced during the period, with a combined minimum value exceeding $280 million. The largest was a 10-year, $170 million full stack and cardiology contract with the University of Colorado, signed on 3 July 2025. Other notable contracts included a 5-year $44 million agreement with Advanced Radiology Management for the Visage Viewer product, and a 7-year $25 million contract with BayCare for the Visage 7 Open Archive. The company also entered the European market with a 5-year, $10 million Viewer and Archive contract with University Hospital Heidelberg in Germany.

Two of the seven new contracts include the company's cardiology offering, bringing the total product offering to what PME's CEO describes as full stack plus one — comprising Viewer, Workflow, Archive, and Cardiology. This expanded product suite increases the average contract value per client and broadens the company's footprint within each health system, creating additional barriers to competitive displacement. Dr Hupert noted that Pro Medicus made more sales in the first half of FY2026 than the company used to make in a full year just two years prior, a statistic that contextualises the pace of commercial acceleration.

Post-Period Contract Activity Through June 2026

The strong contract momentum continued well beyond the reporting period. In the months following December 2025, Pro Medicus announced a series of further contract wins and renewals. These included a 5-year $37 million renewal with Northwestern (April 2026), a 5-year $23 million contract with the University of Maryland (April 2026), a 7-year $90 million deal with Beth Israel Lahey Health (May 2026), a 5-year $28 million renewal with Allegheny Health (June 2026), and a 7-year $16 million contract with TidalHealth (June 2026). The volume and dollar scale of these announcements in what is effectively the first five months of the second half of FY2026 suggests the company's pipeline conversion has maintained its trajectory.

Go-Live Schedule and Revenue Ramp

A distinctive feature of Pro Medicus's revenue model is that contracted revenue is recognised over the life of each contract as scans are processed — meaning revenue does not flow immediately upon signing. The company's implementation schedule is therefore a leading indicator of future revenue growth. During 1H FY2026, six implementations went live, all cloud-based, including the Trinity Health Cohort 1 which went live toward the end of October 2025, limiting its contribution to the half. Dr Hupert stated that a further seven go-lives are planned before the end of the financial year, including three additional Trinity cohorts. Each new go-live adds an incremental and recurring revenue stream that compounds the base for future periods.

Investment in 4DMedical and Balance Sheet Position

The $10 million investment in 4DMedical Limited in July 2025 is a strategically interesting data point. By December 2025, the unrealised pre-tax gain on this investment was $149.1 million, implying a market-implied value for the 4DMedical stake that is approximately 16 times the original cost over roughly five months. While this gain is non-cash and non-recurring in terms of its impact on operating earnings, it demonstrates PME management's ability to identify adjacencies in the healthcare technology sector. The company's ongoing commitment to a debt-free balance sheet and its disciplined capital management — returning cash through dividends and buybacks while still growing its cash position — reflects a financial conservatism that is relatively rare among high-growth technology companies.

Conclusion

Pro Medicus delivered a half-year result that was notable on every meaningful financial metric: revenue growth of 28.4%, underlying PBT growth of nearly 30%, EBIT margins at a multi-year high of 73%, a debt-free balance sheet, and more than $280 million in new contract minimum value signed in a single six-month period. The post-period contract announcements extending into June 2026, including a $90 million deal with Beth Israel Lahey Health, reinforce that the commercial momentum has continued. With seven planned go-lives before year end and an expanding product suite that now includes cardiology, Pro Medicus is building an increasingly deep and diverse revenue base that investors and analysts tracking premium-growth ASX healthcare technology stocks will find difficult to overlook.